Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering
Phase 4
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000002531
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria included patients who exhibited severe hypertension (clinic systolic >= 180 mmHg and/or diastolic BP >= 110 mmHg), renal insufficiency (estimated glomerular filtration < 30 ml/min/1.73 m2), women who were nursing or pregnant, clinically significant heart disease, moderate-to-severe hepatic dysfunction, and known hypersensitivity to any component of the study medications.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A. Clinic blood pressure B. Home blood pressure profile C. Renal function including eGFR and urinary protein/albumin excretion. D. Vascular function including central BP, AI, baPWV and ABI.
- Secondary Outcome Measures
Name Time Method 1. Glucose metabolism including FPG, IRI, HOMA-IR, HbA1C. 2. Lipid metabolism including T-cho, LDL-cho, HDL-cho, and TG. 3. Activity of sympathetic nerve and renin-angiotensinsystem including PRA, PAC, catecholamine, and urinary angiotensinogen. 4. Oxidative stress marlers including pentosidine and urinary L-FABP. 5. Cardiac function including BNP, cardiac echographic parameters. 6. CBC, electrolyte, and liver function. 7. Adverse events.